Loading Events

« All Events

  • This event has passed.

Tumour Models London 2017

05/12/2017 - 06/12/2017

Extract More Value from Predictable Preclinical Data to Enhance Translational Decision Making
CLICK HERE TO FIND OUT MORE

Tumour Models London (London, 5-7 December) takes a reinvigorated approach towards closing the translational gap between predictable preclinical validation and successful clinical development.

Learn how industry leaders are harnessing next generation in vitro and in vivotechniques to better predict efficacy and toxicity into the clinic; and fast track suitable drug candidates by effectively and accurately mimicking the tumour microenvironment. Discover innovative ways in which the industry is developing humanised mice and generating preclinical data, to advance immunotherapies across the translational gap.

As 2017 comes to a close, join the most trusted and assured meeting dedicated to help you predict the clinical outcome of your drug candidates more accurately through the effective application of well characterised and predictable preclinical models.

Expert speaker highlights:

  • Sara Colombetti, Ph.D, Head of Oncology Discovery Pharmacology, Roche Innovation Centre
  • Dr. María José Oliva Martin, Senior Scientist Preclinical Cell Biology, Immunocore Ltd
  • Frank Schnieders, CEO, Provecs Medical
  • Michael Rugaard Jensen, Head of Drug Discovery Pharmacology, Novartis
  • Anita Seshire, Ph.D, Head of Laboratory, Oncology; Cellular Pharmacology, Merck
  • Elizabeth Hardaker, Team Leader, AstraZeneca

CLICK HERE TO FIND OUT MORE

Details

Start:
05/12/2017
End:
06/12/2017
Event Category:
Website:
http://tumour-models.com/

Organizer

Hanson Wade
Phone:
+44 (0)203 141 8700
Email:
info@hansonwade.com
Website:
https://hansonwade.com/

Venue

De Vere Canary Wharf
1 Westferry Circus, Canary Wharf
London, E14 4HD United Kingdom
+ Google Map
Phone:
+44 871 222 4832
Website:
phcompany.com

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.